6851-80-5

Basic information

• Product Name: 2-METHOXY-N-METHYLBENZYLAMINE 97
• Synonyms: 2-METHOXY-N-METHYLBENZYLAMINE 97;N-(2-METHOXYBENZYL)-N-METHYLAMINE;2-Methoxy-N-methylbenzylamine;2-METHOXY-N-METHYLBE;2-Methoxy-N-methylbenzylamine 97%;(2-methoxybenzyl)methylamine;(2-methoxybenzyl)-methyl-amine;N-methyl-o-methoxybenzylamine
• CAS NO: 6851-80-5
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.21
• Product Categories: Amines;C9 to C10;Nitrogen Compounds
• Mol File: 6851-80-5.mol

Chemical Properties

• Boiling Point: 234-235 °C(lit.)
• Flash Point: 222 °F
• Appearance: Colorless/Liquid
• Density: 1.015 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.195mmHg at 25°C
• Refractive Index: n20/D 1.5325(lit.)
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-METHOXY-N-METHYLBENZYLAMINE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXY-N-METHYLBENZYLAMINE 97(6851-80-5)
• EPA Substance Registry System: 2-METHOXY-N-METHYLBENZYLAMINE 97(6851-80-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: 8
• Hazardous Substances Data: 6851-80-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-METHOXY-N-METHYLBENZYLAMINE 97 is used as a key intermediate in the synthesis of drugs, specifically for the production of antihistamines and antitussives. Its role in drug synthesis is vital for creating medications that address allergic reactions and suppress coughs.
Used in Agrochemical Industry:
In the agrochemical sector, 2-METHOXY-N-METHYLBENZYLAMINE 97 is utilized as an intermediate in the manufacturing of pesticides and herbicides. Its contribution to these products helps in controlling, preventing, and killing unwanted plants and pests, thereby supporting agricultural productivity and crop protection.
Used in Photographic Chemicals Industry:
2-METHOXY-N-METHYLBENZYLAMINE 97 also finds application in the production of photographic chemicals, where it plays a role in the development and processing of photographic films and papers, contributing to the imaging and preservation of photographic images.

InChI:InChI=1/C9H13NO/c1-10-7-8-5-3-4-6-9(8)11-2/h3-6,10H,7H2,1-2H3/p+1

Upstream product

• 135-02-4 ortho-anisaldehyde 
• 74-89-5 methylamine 
• 3400-35-9 2-methoxy-N-methylbenzamide 
• 6850-57-3 2-methoxybenzylamine 
• 616-38-6 carbonic acid dimethyl ester 
• 593-51-1 methylamine hydrochloride 
• 858799-11-8 N-(2-methoxy-benzyl)-N-methyl-formamide 
• 333-27-7 methyl trifluoromethanesulfonate 

Downstream Products

• 802884-12-4 benzo[1,3]dioxol-5-ylmethyl-(2-methoxy-benzyl)-methyl-amine 
• 801199-67-7 (2-methoxy-benzyl)-(4-methoxy-benzyl)-methyl-amine 
• 100054-98-6 N-(2-hydroxyethyl)-N-(2-methoxylbenzyl)methylamine 
• 58774-83-7 [(2-methoxyphenyl)methyl]dimethylamine 
• 33499-30-8 N-(2-methoxybenzylidene)methanamine N-oxide 
• 475200-56-7 N-(2-methoxybenzyl)-N-methyl acetoacetamide 
• 106842-08-4 [2-(3-amino-propoxy)-ethyl]-(2-methoxy-benzyl)-methyl-amine 
• 102451-22-9 3-{2-[(2-methoxy-benzyl)-methyl-amino]-ethoxy}-propionitrile 
• 1147092-65-6 (3,4-dimethoxyphenyl)-(4-{[(2-methoxybenzyl)methylamino]methyl}phenyl)methanone 
• 877264-39-6 C₁₉H₁₉NO₂S 

Relevant articles and documents

Epoxide-Mediated Stevens Rearrangements of α-Amino-Acid-Derived Tertiary Allylic, Propargylic, and Benzylic Amines: Convenient Access to Polysubstituted Morpholin-2-ones

A new strategy has been established for the synthesis of polysubstituted morpholin-2-ones through Stevens rearrangements of tertiary amines via in situ activation with epoxides. A range of α-amino acid-derived tertiary allylic, propargylic, and benzylic amines reacted with epoxides in the presence of zinc halide catalysts to afford structurally diverse allyl-, allenyl-, and benzyl-substituted morpholin-2-ones, respectively, in moderate-to-good yields with high regioselectivity. The process involves [2,3]- and [1,2]-Stevens rearrangements of quaternary ammonium ylide intermediates and constitutes a very convenient method to prepare polysubstituted morpholin-2-ones through tandem formation of C?N, C?O, and C?C bonds. Moreover, replacing epoxides with aziridines permitted the synthesis of polysubstituted piperazin-2-ones.

Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease

A series of novel phthalimide-alkylamine derivatives were synthesized and evaluated as multi-functions inhibitors for the treatment of Alzheimer's disease (AD). The results showed that compound TM-9 could be regarded as a balanced multi-targets active molecule. It exhibited potent and balanced inhibitory activities against ChE and MAO-B (huAChE, huBuChE, and huMAO-B with IC50 values of 1.2 μM, 3.8 μM and 2.6 μM, respectively) with low selectivity. Both kinetic analysis of AChE inhibition and molecular modeling study suggested that TM-9 binds simultaneously to the catalytic active site and peripheral anionic site of AChE. Interestingly, compound TM-9 abided by Lipinski's rule of five. Furthermore, our investigation proved that TM-9 indicated weak cytotoxicity, and it could cross the blood-brain barrier (BBB) in vitro. The results suggest that compound TM-9, an interesting multi-targeted active molecule, offers an attractive starting point for further lead optimization in the drug-discovery process against Alzheimer's disease.

Amidation of unactivated ester derivatives mediated by trifluoroethanol

A catalytic amidation protocol mediated by 2,2,2-trifluoroethanol has been developed, facilitating the condensation of unactivated esters and amines, furnishing both secondary and tertiary amides. The complete scope and limitations of the method are described, along with modified conditions for challenging substrates such as acyclic secondary amines and chiral esters with retention of chiral integrity.

Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease

A novel series of ferulic acid-memoquin hybrids were designed, synthesized and evaluated as multifunctional agents for the treatment of Alzheimer's disease (AD). The in vitro studies showed that most of the compounds exhibited a significant ability to inhibit acetylcholinesterase (AChE) (IC50 of 3.2-34.7 μM) and self-induced β-amyloid (Aβ1-42) aggregation (30.8-39.1%, 25 μM), to act as potential antioxidants (ORAC-FL value of 0.9-1.3). In particular, compound 17d had the greatest ability to inhibit AChE (IC50 = 3.2 μM), and Aβ1-42 aggregation (30.8%) was also an excellent antioxidant and neuroprotectant. Moreover, it is capable of disaggregating self-induced Aβ aggregation. Furthermore, 17d could cross the blood-brain barrier (BBB) in vitro. The results showed that compound 17d is a potential multifunctional agent for the treatment of AD.

Design, synthesis and evaluation of chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer's disease

A series of chromone-2-carboxamido-alkylbenzylamines were designed, synthesized and evaluated as multifunctional agents for the treatment of Alzheimer's disease (AD). The results showed that most of these compounds exhibited good multifunctional activities. Among them, compound 49 displayed excellent inhibitory potency toward acetylcholinesterase (AChE), moderate anti-oxidative activity, selective biometal chelating, and possessed good inhibitory effects on self-induced and Cu2+-induced Aβ aggregation. Both kinetic analysis of AChE inhibition and molecular modeling study indicated that 49 was a mixed-type inhibitor, binding simultaneously to the catalytic active site and peripheral anionic site of AChE. These results suggested that 49 might be a potential multifunctional agent for AD treatment.

Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease

A series of genistein derivatives with carbon spacer-linked alkylbenzylamines were designed, synthesized and tested as multifunctional agents for the treatment of Alzheimer's disease (AD). The results showed that most of these compounds exhibited good acetylcholinesterase (AChE) inhibitory activity, with moderate-to-good anti-oxidative activity. Specifically, compounds 10b, 19d and 25d exhibited significant inhibition of β-amyloid (Aβ) aggregation and exhibited metal chelating properties. In particular, 25d inhibited: self-induced Aβ1-42 aggregation, Cu 2+-induced Aβ1-42 aggregation, and human AChE-induced Aβ1-40 aggregation by 35%, 77.8%, and 36.2%, respectively. Moreover, both kinetic analysis of AChE inhibition and the molecular modeling study suggested that 25d binds simultaneously to catalytic active site and peripheral anionic site of AChE. More importantly, compound 25d disassembled the well-structured Aβ fibrils generated by Cu2+-induced Aβ aggregation by 72.1%. Furthermore, the step-down passive avoidance test showed this compound significantly reversed scopolamine-induced memory deficit in mice. These results suggest that 25d may be a promising multifunctional agent for AD treatment.

Selective monomethylation of primary amines with simple electrophiles

Direct monomethylation of primary amines with methyl triflate was achieved with high selectivity (up to 96%). The key point of this single methyl transfer stems from the use of HFIP as the solvent that interferes with amines and avoids overmethylation.

4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors

Novel 4-phenyl tetrahydroisoquinolines that inhibit both dopamine and norepinephrine transporters were designed and prepared. In this Letter, we describe the synthesis, in vitro activity and associated structure-activity relationships of this series. We also report the ex vivo NET occupancy of a representative compound, 41.

Highly enantioselective synthesis of tetrahydroquinolines via cobalt(II)-catalyzed tandem 1,5-hydride transfer/cyclization

A chiral catalyst prepared from N,N′-dioxide and Co(BF 4)2·6H2O was applied in the asymmetric hydride transfer initiated cyclization reaction, giving optically active tetrahydroquinolines in good yields with high enantioselectivities under mild reaction conditions. Meanwhile, in light of the absolute configuration of the product, a possible working model was proposed to explain the origin of the activation and asymmetric induction.

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R14; with R1, R2, R3, R4, R5, R6, R7, R8, and R14 defined herein.